According to PARI Pharma, the company has licensed a formulation of liposomal cyclosporine A for the treatment of bronchiolitis obliterans syndrome (BOS) to Breath Therapeutics.
Breath Therapeutics, a spin off of PARI, recently announced that it has raised €43.5 million in Series A Financing, which it will use for Phase 3 trials of the product, regulatory submission and preparations for commercialization. The liposomal cyclosporine A formulation is being developed in collaboration with Aldo Iacono, Medical Director of the Lung Transplant Program at the University of Maryland Medical Center.
Breath Therapeutics CEO Jens Stegemann said, “BOS is one of the most devastating lung diseases and still today, no effective therapy is available. Our strategy with this lead program from PARI Pharma is to deposit high concentrations of an immunosuppressive agent directly into the small airways of the lung.”
PARI Pharma President Martin Knoch commented, “The team at Breath Therapeutics has the expertise and focus to bring the first lung-targeted BOS therapy through clinical development and hopefully onto the market. For PARI Pharma, it is highly rewarding to see a project that we started advancing into late-stage clinical development and providing BOS patients new hope.”
Read the PARI Pharma press release on the licensing agreement.
Read the Breath Technologies press release on its funding.
